Torsten Haferlach
Ludwig Maximilian University of Munich
11 Papers
438 Citations
Torsten Haferlach is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Biology & Neuroblastoma RAS viral oncogene homolog. The author has an hindex of 11, co-authored 11 publications.
Chat about Author
Papers
Frequent pathway mutations of splicing machinery in myelodysplasia
Kenichi Yoshida,Masashi Sanada,Yuichi Shiraishi,Daniel Nowak,Yasunobu Nagata,Ryo Yamamoto,Yusuke Sato,Aiko Sato-Otsubo,Ayana Kon,Masao Nagasaki,George Chalkidis,Yutaka Suzuki,Masashi Shiosaka,Ryoichiro Kawahata,Tomoyuki Yamaguchi,Makoto Otsu,Naoshi Obara,Mamiko Sakata-Yanagimoto,Ken Ishiyama,Hiraku Mori,Florian Nolte,Wolf-Karsten Hofmann,Shuichi Miyawaki,Sumio Sugano,Claudia Haferlach,H. Phillip Koeffler,H. Phillip Koeffler,Lee Yung Shih,Torsten Haferlach,Shigeru Chiba,Hiromitsu Nakauchi,Satoru Miyano,Seishi Ogawa +32 more
TL;DR: The results provide the first evidence indicating that genetic alterations of the major splicing components could be involved in human pathogenesis, also implicating a novel therapeutic possibility for myelodysplasia.
2K
Frequent Pathway Mutations of Splicing Machinery in Myelodysplasia
Kenichi Yoshida,Masashi Sanada,Yuichi Shiraishi,Daniel Nowak,Yasunobu Nagata,Ryo Yamamoto,Yusuke Sato,Aiko Sato-Otsubo,Ayana Kon,Masao Nagasaki,George Chalkidis,Yutaka Suzuki,Makoto Otsu,Naoshi Obara,Mamiko Sakata-Yanagimoto,Ken Ishiyama,Hiraku Mori,Florian Nolte,Wolf-Karsten Hofmann,Shuichi Miyawaki,Sumio Sugano,Claudia Haferlach,H. Phillip Koeffler,Lee-Yung Shih,Torsten Haferlach,Shigeru Chiba,Hiromitsu Nakauchi,Satoru Miyano,Seishi Ogawa +28 more
TL;DR: In this article, the authors performed whole-exome sequencing of 29 cases showing myelodysplasia and identified a total of 268 somatic mutations or 9.2 mutations per sample were identified.
433
Implications of NRAS mutations in AML: a study of 2502 patients.
TL;DR: There was a trend to better survival in most subgroups, especially when other molecular markers (FLT3-LM, MLL-PTD, and NPM) were taken into account, and there was a significant prognostic impact of NRAS(mut) for overall survival, event- free survival, and disease-free survival.
317
Next-Generation Sequencing Technology Reveals a Characteristic Pattern of Molecular Mutations in 72.8% of Chronic Myelomonocytic Leukemia by Detecting Frequent Alterations in TET2, CBL, RAS, and RUNX1
Alexander Kohlmann,Vera Grossmann,Hans-Ulrich Klein,Sonja Schindela,Tamara Weiss,Beray Kazak,Frank Dicker,Susanne Schnittger,Martin Dugas,Wolfgang Kern,Claudia Haferlach,Torsten Haferlach +11 more
TL;DR: Next-generation sequencing screening has been demonstrated to support a comprehensive characterization of the molecular background in CMML and a pattern of molecular mutations translates into different biologic and prognostic categories of CMML.
311
The role of different genetic subtypes of CEBPA mutated AML.
Annette Fasan,Claudia Haferlach,Tamara Alpermann,Sabine Jeromin,Vera Grossmann,C Eder,Sandra Weissmann,Frank Dicker,Alexander Kohlmann,Sonja Schindela,Wolfgang Kern,Torsten Haferlach,Susanne Schnittger +12 more
TL;DR: It is proposed that only CEBPAdm should be considered as an entity in the WHO classification of AML and should be clearly distinguished from CEBPAsm AML.
174